Integral Molecular awarded $3.5M contract from NIH to study Ebola and Hepatitis C virus antibody response

PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. has been awarded a five year $3.5 million contract to study the human immune response to Ebola virus and hepatitis C virus (HCV). This award enables Integral Molecular to understand how human antibodies protect (or fail to protect) against these viruses. Using its proprietary Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular will identify how antibodies target binding structures, or epitopes, on Ebola and HCV, which will facilitate the development of vaccines and therapeutics against these major health threats. Click here to read more.